Aptose Q2 net loss $14.1M; TUS/VEN doublet 50% CRc; Hanmi commits up to $7M

Aptose Biosciences Inc.

2023-Q2 EPS reported -$4.47

TUS/VEN doublet: 50% CRc (5/10 evaluable); 44% CRc in prior-venetoclax failures (4/9); 43% in FLT3-WT (3/7).
Hanmi Pharma commits up to $7M or 19.99% ownership in two tranches; first $3M by Aug-end conditional on TSX listing.
Q2 net loss $14.1M vs $10.6M prior year; cash $23.3M at June 30, expected to fund operations through March 2024.
FDA End of Phase 1 meeting completed; monotherapy RP2D of 80 mg daily confirmed; accelerated path remains open.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Aptose Biosciences Inc. reported three months ended June 30, 2023 results: net income $(14,129 ) thousand, EPS $(2.27 ) per share.

Period: three months ended June 30, 2023
Net income: $(14,129 ) thousand
EPS: $(2.27 ) per share
Result: reported results

Exact text from the filing

Aptose Reports Results for the Second Quarter 2023

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-005225

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.